UBS Group »

Rapt Therapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2025-12-31 $2.2M 66k 33.87
2025-09-30 $743k 29k 25.79
2025-06-30 $30k 3.7k 8.00

More positions owned by UBS Group

NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Amazon (AMZN)
Broadcom (AVGO)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl C (GOOG)
Invesco Qqq Tr Unit Ser 1 (QQQ)
JPMorgan Chase & Co. (JPM)
Ubs Group SHS (UBS)
Ishares Tr Russell 2000 Etf (IWM)
Spdr Gold Tr Gold Shs (GLD)
Tesla Motors (TSLA)

View all positions for UBS Group

Top funds holding Rapt Therapeutics

TCG Crossover Management
Fcpm Iii Services B.v.
OrbiMed Advisors
Rtw Investments
Foresite Capital Management VI
Siren
Vanguard Group
Frazier Life Sciences Management
Ikarian Capital
Braidwell
Soleus Capital Management
Nantahala Capital Management
Caligan Partners
State Street Corporation
Dr. Jeffrey R. Jay, M.D.

View all funds holding Rapt Therapeutics